In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...

Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted ...

Shares of Corvus Pharmaceuticals CRVS gained 13.9% on Sept. 10 after the company announced the initiation of a phase III ...

Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology ...

Those looking for a big night with the best Netflix action movies have come to the right place. Netflix’s selection of high-octane action movies is so vast that there’s something for everyone ...

Tango Therapeutics is a high-risk, high-reward opportunity in the field of PRMT5-inhibitor drugs targeting MTAP-deleted ...

Data from the study showed that the drug reduced the risk of disease progression or death by nearly half when compared to Keytruda ... believes that this dual mechanism differentiates ivonescimab ...